These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Can established CT attenuation and washout criteria for adrenal adenoma accurately exclude pheochromocytoma? Patel J; Davenport MS; Cohan RH; Caoili EM AJR Am J Roentgenol; 2013 Jul; 201(1):122-7. PubMed ID: 23789665 [TBL] [Abstract][Full Text] [Related]
24. Computed tomography (CT) scan identified necrosis, but is it a reliable single parameter for discerning between malignant and benign adrenocortical tumors? Garay-Lechuga D; Pérez-Soto RH; Hernández-Acevedo JD; Butrón-Hernández D; Sierra-Salazar M; Pantoja-Millán JP; Herrera MF; Velázquez-Fernández D Surgery; 2022 Jan; 171(1):104-110. PubMed ID: 34183180 [TBL] [Abstract][Full Text] [Related]
25. Microarray gene expression and immunohistochemistry analyses of adrenocortical tumors identify IGF2 and Ki-67 as useful in differentiating carcinomas from adenomas. Soon PS; Gill AJ; Benn DE; Clarkson A; Robinson BG; McDonald KL; Sidhu SB Endocr Relat Cancer; 2009 Jun; 16(2):573-83. PubMed ID: 19218281 [TBL] [Abstract][Full Text] [Related]
26. A case of adrenocortical carcinoma diagnosed 9 years after the discovery of adrenal incidentaloma. Aono D; Kometani M; Asano T; Konishi S; Karashima S; Ikeda H; Nohara T; Yoneda T Endocr J; 2022 Dec; 69(12):1415-1421. PubMed ID: 35934796 [TBL] [Abstract][Full Text] [Related]
28. Pediatric adrenocortical neoplasms: can imaging reliably discriminate adenomas from carcinomas? Flynt KA; Dillman JR; Davenport MS; Smith EA; Else T; Strouse PJ; Caoili EM Pediatr Radiol; 2015 Jul; 45(8):1160-8. PubMed ID: 25794486 [TBL] [Abstract][Full Text] [Related]
29. Clinical and imaging presentations are associated with function in incidental adrenocortical adenomas: a retrospective cohort study. Hamidi O; Shah M; Zhang CD; Lazik N; Li D; Singh S; Iñiguez-Ariza NM; Raman R; Hurtado MD; Carafone L; Khanna A; Yan Q; Natt N; Hartman RP; McKenzie T; Young WF; Bancos I Eur J Endocrinol; 2024 Jul; 191(1):47-54. PubMed ID: 38941271 [TBL] [Abstract][Full Text] [Related]
30. [Comparative clinical analysis of histological systems of adrenocortical tumors diagnosis]. Bokhyan VY; Stilidi IS; Pavlovskaya AI Vopr Onkol; 2015; 61(6):925-31. PubMed ID: 26995980 [TBL] [Abstract][Full Text] [Related]
31. Analysis of histological and immunohistochemical patterns of benign and malignant adrenocortical tumors by computerized morphometry. Dalino Ciaramella P; Vertemati M; Petrella D; Bonacina E; Grossrubatscher E; Duregon E; Volante M; Papotti M; Loli P Pathol Res Pract; 2017 Jul; 213(7):815-823. PubMed ID: 28554744 [TBL] [Abstract][Full Text] [Related]
32. CT features and quantification of the characteristics of adrenocortical carcinomas on unenhanced and contrast-enhanced studies. Zhang HM; Perrier ND; Grubbs EG; Sircar K; Ye ZX; Lee JE; Ng CS Clin Radiol; 2012 Jan; 67(1):38-46. PubMed ID: 21783181 [TBL] [Abstract][Full Text] [Related]
33. Diagnostic and prognostic assessments of adrenocortical carcinomas by pathological features, immunohistochemical markers and reticular histochemistry staining. Gan W; Han X; Gong Y; Yang Y; Wang C; Zhang Z Diagn Pathol; 2024 May; 19(1):71. PubMed ID: 38802933 [TBL] [Abstract][Full Text] [Related]
34. The adrenal mass: correlation of histopathology with imaging. Yip L; Tublin ME; Falcone JA; Nordman CR; Stang MT; Ogilvie JB; Carty SE; Yim JH Ann Surg Oncol; 2010 Mar; 17(3):846-52. PubMed ID: 19960266 [TBL] [Abstract][Full Text] [Related]
35. Differentiation between adrenocortical carcinoma and lipid-poor adrenal adenoma using a multiparametric MRI-based diagnostic algorithm. Oloukoi C; Dohan A; Gaillard M; Hoeffel C; Groussin-Rouiller L; Bertherat J; Jouinot A; Assié G; Fuks D; Sibony M; Soyer P; Jannot AS; Barat M Diagn Interv Imaging; 2024 Oct; 105(10):355-363. PubMed ID: 38575426 [TBL] [Abstract][Full Text] [Related]
36. Uptake of 18F-FDG in Adrenal Adenomas Is Associated With Unenhanced CT Value and Constituent Cells. Murayama R; Nishie A; Hida T; Baba S; Inokuchi J; Oda Y; Honda H Clin Nucl Med; 2019 Dec; 44(12):943-948. PubMed ID: 31490313 [TBL] [Abstract][Full Text] [Related]
37. Serum inhibin pro-αC is a tumor marker for adrenocortical carcinomas. Hofland J; Feelders RA; van der Wal R; Kerstens MN; Haak HR; de Herder WW; de Jong FH Eur J Endocrinol; 2012 Feb; 166(2):281-9. PubMed ID: 22127493 [TBL] [Abstract][Full Text] [Related]
38. DNA and kinetic heterogeneity during the clonal evolution of adrenocortical proliferative lesions. Blanes A; Diaz-Cano SJ Hum Pathol; 2006 Oct; 37(10):1295-303. PubMed ID: 16949934 [TBL] [Abstract][Full Text] [Related]
39. [Clinicopathologic features and expression of epidermal growth factor receptor and vascular endothelial growth factor in adrenocortical tumors]. Wang CP; Zhang J; Gao J; Liu PP; Wu SF; Zeng X; Liang ZY Zhonghua Bing Li Xue Za Zhi; 2012 Oct; 41(10):686-90. PubMed ID: 23302311 [TBL] [Abstract][Full Text] [Related]